Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;200(6):1250-1255.
doi: 10.1016/j.juro.2018.06.013. Epub 2018 Jun 7.

Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort

Affiliations

Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort

Karim Marzouk et al. J Urol. 2018 Dec.

Abstract

Purpose: Active surveillance is the preferred management of low risk prostate cancer. Cancer specific anxiety during active surveillance remains under studied. We evaluated long-term anxiety in men on active surveillance to determine whether interventions must be tailored to improve adherence.

Materials and methods: A total of 413 men enrolled in active surveillance at a single tertiary care center completed quality of life surveys as part of routine care. A modified version of the MAX-PC (Memorial Anxiety Scale for Prostate Cancer) was used to determine cancer specific anxiety. Generalized estimating equations were applied to evaluate the association between anxiety and the duration on surveillance. Additionally, we examined associations between anxiety and patient age, marital status, Gleason score, the number of positive cores, family history and overall health.

Results: Median patient age was 61 years, median prostate specific antigen at diagnosis was 4.4 ng/ml and 95% of the patients had Gleason 6 disease. Median time from the initiation of active surveillance to the last survey was 3.7 years. There was a 29% risk of reporting cancer specific anxiety within year 1. Anxiety significantly decreased with time (OR 0.87, 95% CI 0.79-0.95, p = 0.003). Pathological and demographic characteristics were not associated with anxiety after adjusting for time on surveillance.

Conclusions: In men undergoing active surveillance we observed a moderate risk of cancer specific anxiety which significantly decreases with time. Those considering conservative management can be informed that, although it is common to experience some anxiety initially, most patients rapidly adjust and report low anxiety levels within 2 years.

Keywords: anxiety; patient reported outcome measures; prostatic neoplasms; quality of life; watchful waiting.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Univariable predicted risk and 95% confidence interval of prostate cancer anxiety by time from active surveillance to survey date (n=413). The shaded region represents the distribution of the times from active surveillance to survey response.

Comment in

  • Editorial Comment.
    van den Bergh RCN, van der Poel HG, Murphy DG. van den Bergh RCN, et al. J Urol. 2018 Dec;200(6):1254-1255. doi: 10.1016/j.juro.2018.06.094. Epub 2018 Sep 5. J Urol. 2018. PMID: 30193091 No abstract available.

References

    1. Etzioni R, Penson DF, Legler JM et al.: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002 - PubMed
    1. Bokhorst LP, Valdagni R, Rannikko A et al.: A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur Urol, 70: 954, 2016 - PubMed
    1. Klotz L, Vesprini D, Sethukavalan P et al.: Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol, 33: 272, 2015 - PubMed
    1. Tosoian JJ, Mamawala M, Epstein JI et al.: Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol, 33: 3379, 2015 - PMC - PubMed
    1. Donovan JL, Hamdy FC, Lane JA et al.: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med, 375: 1425, 2016 - PMC - PubMed

MeSH terms

Substances